Cowen and Company set a $147.00 target price on Johnson & Johnson (NYSE:JNJ) in a research report released on Friday morning. The firm currently has a buy rating on the stock.

Other analysts have also recently issued reports about the stock. Royal Bank Of Canada restated a buy rating and set a $138.00 target price on shares of Johnson & Johnson in a research report on Wednesday, July 12th. BidaskClub lowered shares of Johnson & Johnson from a strong-buy rating to a buy rating in a research report on Saturday, July 1st. UBS AG reissued a buy rating and issued a $148.00 price objective (up from $136.00) on shares of Johnson & Johnson in a research report on Wednesday, July 19th. Zacks Investment Research raised shares of Johnson & Johnson from a hold rating to a buy rating and set a $148.00 price objective on the stock in a research report on Thursday, July 27th. Finally, Credit Suisse Group reissued a buy rating on shares of Johnson & Johnson in a research report on Friday, August 4th. Five equities research analysts have rated the stock with a sell rating, nine have issued a hold rating and nine have assigned a buy rating to the company. Johnson & Johnson presently has an average rating of Hold and an average target price of $134.79.

Johnson & Johnson (NYSE:JNJ) opened at 133.22 on Friday. The stock has a market cap of $357.56 billion, a P/E ratio of 22.54 and a beta of 0.78. Johnson & Johnson has a 12-month low of $109.32 and a 12-month high of $137.08. The stock has a 50 day moving average price of $132.23 and a 200 day moving average price of $129.87.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Tuesday, July 18th. The company reported $1.83 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.79 by $0.04. The firm had revenue of $18.84 billion for the quarter, compared to analysts’ expectations of $18.94 billion. Johnson & Johnson had a net margin of 22.52% and a return on equity of 26.76%. The business’s revenue was up 1.9% compared to the same quarter last year. During the same period in the prior year, the company earned $1.74 EPS. On average, analysts forecast that Johnson & Johnson will post $7.18 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Cowen and Company Analysts Give Johnson & Johnson (JNJ) a $147.00 Price Target” was originally reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece of content on another website, it was copied illegally and republished in violation of U.S. & international copyright and trademark law. The original version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/10/09/cowen-and-company-analysts-give-johnson-johnson-jnj-a-147-00-price-target.html.

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, September 12th. Stockholders of record on Tuesday, August 29th were paid a dividend of $0.84 per share. The ex-dividend date of this dividend was Friday, August 25th. This represents a $3.36 dividend on an annualized basis and a dividend yield of 2.52%. Johnson & Johnson’s dividend payout ratio is presently 56.76%.

In other news, VP Dominic J. Caruso sold 82,591 shares of the stock in a transaction that occurred on Thursday, July 20th. The shares were sold at an average price of $136.72, for a total transaction of $11,291,841.52. Following the transaction, the vice president now directly owns 226,693 shares in the company, valued at $30,993,466.96. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, VP Paulus Stoffels sold 102,692 shares of the stock in a transaction that occurred on Monday, July 24th. The shares were sold at an average price of $133.14, for a total transaction of $13,672,412.88. Following the transaction, the vice president now owns 230,342 shares in the company, valued at $30,667,733.88. The disclosure for this sale can be found here. 0.19% of the stock is currently owned by company insiders.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Harding Loevner LP bought a new position in shares of Johnson & Johnson during the second quarter valued at approximately $106,000. Mitsubishi UFJ Securities Holdings Co. Ltd. boosted its stake in shares of Johnson & Johnson by 29.9% during the second quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 870 shares of the company’s stock valued at $115,000 after purchasing an additional 200 shares in the last quarter. Lenox Wealth Advisors Inc. boosted its stake in shares of Johnson & Johnson by 0.6% during the second quarter. Lenox Wealth Advisors Inc. now owns 876 shares of the company’s stock valued at $116,000 after purchasing an additional 5 shares in the last quarter. Mountain Capital Investment Advisors Inc bought a new position in shares of Johnson & Johnson during the second quarter valued at approximately $124,000. Finally, Harel Insurance Investments & Financial Services Ltd. boosted its stake in shares of Johnson & Johnson by 241.0% during the first quarter. Harel Insurance Investments & Financial Services Ltd. now owns 1,190 shares of the company’s stock valued at $149,000 after purchasing an additional 841 shares in the last quarter. Hedge funds and other institutional investors own 65.90% of the company’s stock.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Analyst Recommendations for Johnson & Johnson (NYSE:JNJ)

Receive News & Stock Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related stocks with our FREE daily email newsletter.